Dermata Therapeutics -CW26DRMAWPreferred / convertible
13F holders, Q1 2025 (March 31)3holders −2
0new positions
2sold out
$0.48avg. 13F price*
At the end of Q1 2025, 3 institutions reported holding Dermata Therapeutics -CW26 (DRMAW) in their 13F filings, down 2 from Q4 2024. 0 opened new positions and 2 sold out. The largest holders were Boothbay Fund Management, LLC ($13K), Two Sigma Securities, LLC ($231) and UBS Group AG ($44).
- Company
- Dermata Therapeutics -CW26
- CUSIP
- 249845116
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $15 |
All 13F filers, Q4 2024 → Q1 2025: 358 shares bought and 2,979 shares sold, net −2,621 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Boothbay Fund Management, LLC | — | No change | 12,000 | $13K |
| Two Sigma Securities, LLC | — | Add +2.8% | 13,215 | $231 |
| UBS Group AG | — | Reduce -36.8% | 2,617 | $44 |
"% of holder's portfolio" is DRMAW's weight in each manager's 13F, not the share of Dermata Therapeutics -CW26 the manager owns.